09 December 2020: Clinical Research
Efficacy and Safety of Image-Guided Intensity-Modulated Radiation Therapy and Volumetric Modulated Arc Therapy Combined with Paclitaxel Liposomes and Cisplatin for Locally Advanced Stage IIB–IIIB Cervical Cancer: A Retrospective Study at a Single Center
Meihua Xie ABE* , Xiuxiu Ding BCE* , Aiyu Chen CF , Huiqin Xiao DF , Xiaoye Wang BD , Youhong Wang AC , Huan Zhang ADG*DOI: 10.12659/MSM.927563
Med Sci Monit 2020; 26:e927563
Table 5 Comparison of complications of the studied patients in two groups.
| Parameters | IMRT group (n=63) | VMAT group (n=63) | P-value | ||
|---|---|---|---|---|---|
| Grade I–II | Grade III–IV | Grade I–II | Grade III–IV | ||
| Myelosuppression | 33 (52.4%) | 12 (19.0%) | 21 (33.3%) | 7 (11.1%) | 0.003 |
| Allergic reaction | 11 (17.5%) | 0 (0.0%) | 5 (7.9%) | 0 (0.0%) | 0.108 |
| Gastrointestinal reaction | 41 (65.1%) | 4 (6.3%) | 44 (69.8%) | 3 (4.8%) | 0.688 |
| Muscle & joint pain | 25 (39.7%) | 0 (0.0%) | 20 (31.7%) | 0 (0.0%) | 0.353 |
| Alopecia | 42 (66.7%) | 2 (3.2%) | 36 (57.1%) | 2 (3.2%) | 0.262 |
| Hepatic function damage | 10 (15.9%) | 0 (0.0%) | 8 (12.7%) | 0 (0.0%) | 0.611 |
| Renal function damage | 7 (11.1%) | 0 (0.0%) | 9 (14.3%) | 0 (0.0%) | 0.593 |
| Radiodermatitis | 19 (30.2%) | 0 (0.0%) | 16 (25.4%) | 0 (0.0%) | 0.551 |
| Radiocystitis | 22 (34.9%) | 1 (1.6%) | 24 (38.1%) | 1 (1.6%) | 0.714 |
| Radioproctitis | 38 (60.3%) | 2 (3.2%) | 35 (55.6%) | 1 (1.6%) | 0.466 |
| IMRT – intensity-modulated radiation therapy; VMAT:– volumetric modulated arc therapy. | |||||